Blue Earth Diagnostics to Present New Research Advancing Precision Molecular Imaging at ASTRO 2026

Blue Earth Diagnostics, a subsidiary of Bracco Group known for its work with positron emission tomography (PET) radiopharmaceuticals, is set to present new research at ASTRO 2026. The presentations will explore advances in precision molecular imaging with a focus on cancer care.

The upcoming research will be showcased from September 26 to 30 at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting in Boston, MA. It aims to provide insights into how precision imaging can supplement conventional diagnostic approaches in determining disease location and extent.

Two primary areas of focus include recurrent prostate cancer and brain metastases. For prostate cancer, the studies will analyze the performance of the imaging agents POSLUMA® (flotufolastat F 18) and piflufolastat F 18. Specifically, how they compare in detecting biochemical recurrence in men with low prostate-specific antigen (PSA) levels following radical prostatectomy. Previously, data indicated lower urinary radioactivity with POSLUMA, reducing interference when scanning for recurrent disease.

The brain metastasis study assesses fluciclovine F 18 PET/CT used alongside MRI in post-surgical care, particularly in distinguishing between treatment-related changes and tumor necrosis or pseudoprogression. This single-institution trial involves patients undergoing post-operative fractionated stereotactic radiosurgery.

"Biochemical recurrence of prostate cancer is a significant challenge," noted Dr. Jack R. Andrews, a Urologic Oncologist with the Mayo Clinic, emphasizing the value of head-to-head imaging agent comparisons. Dr. Andrews asserted that these studies illuminate how clinical circumstances might affect detection, aiding the application of molecular imaging in recurrence assessments.

Marco Campione, President and CEO of Blue Earth Diagnostics, affirmed their commitment to innovation and informed patient care through precise molecular imaging technologies. These presentations further the role of PET in oncology, demonstrating its potential in identifying recurrent prostate cancer and better understanding brain metastases post-surgery.